Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
14
11
2023
accepted:
09
04
2024
revised:
28
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
This retrospective study evaluated 35 children (median age 5.2 years; range 0.4-18) with myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary myelofibrosis transplanted from matched sibling donor (MSD) (n = 17) or non-MSD (n = 18) between 2000 and 2022. Conditioning was usually chemotherapy-based (n = 33) and myeloablative (n = 32). Fifteen patients received bone marrow (BM), 14 haematopoietic cells (HC) from peripheral blood (PB), and 6 from cord blood (CB). Day +100 acute GvHD II-IV incidence was significantly lower after MSD-haematopoietic cell transplantation (MSD-HCT) than after non-MSD-HCT [18.8% (4.3-41.1) vs 58.8% (31-78.6); p = 0.01]. Six-year non-relapse mortality (NRM) was 18% (7.1-32.8), relapse incidence was 15.9% (5.6-30.9), progression-free survival (PFS) was 66.1% (47-79.7), GvHD-free relapse-free survival was 50% (30.6-66.7), and overall survival (OS) was 71.1% (51.4-84). Six-year PFS and OS were significantly higher after BM transplantation compared to HCT from other sources [85.1% (52.3-96.1) vs 50.8% (26.3-71), p = 0.03, and 90.9% (50.8-98.7) vs 54% (28.1-74.2), p = 0.01, respectively], whereas NRM was significantly lower [0% vs 32% (12.3-53.9); p = 0.02]. This first multicentre study on outcomes of allogeneic HCT in children with myelofibrosis proves feasibility and curative effect of transplantation in these children, suggests that bone marrow transplantation is associated with better outcomes, and indicates the need for further studies.
Identifiants
pubmed: 38627449
doi: 10.1038/s41409-024-02286-3
pii: 10.1038/s41409-024-02286-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Arber DA, Orazi A, Hasserjia RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Hofmann I. Myeloproliferative neoplasms in children. J Hematopathol. 2015;8:143–57.
doi: 10.1007/s12308-015-0256-1
Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102:7–17.
doi: 10.3324/haematol.2014.113845
pubmed: 27909216
pmcid: 5210228
Vannucchi AM, Gugielmelli P Molecular prognostication in Ph-negative MPNs in 2022. ASH Education Program - Hematology 2022; pp. 225-34.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95:1599–613.
doi: 10.1002/ajh.26008
pubmed: 32974939
Ianotto J-C, Curio-Garcia N, Lauermanova M, Radia D, Kiladjian J-J, Harrison CN. Characteristics and outcomes of patients with essential throbocythemia or polycythemia vera diagnosed before 20 years of age: a systemic review. Haematologica. 2019;104:11580–1588.
doi: 10.3324/haematol.2018.200832
Sobas M, Kiladijan JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022;6:5171–83.
doi: 10.1182/bloodadvances.2022007201
pubmed: 35802458
pmcid: 9631631
Kucine N, Al.-Kawaaz M, Hajje D, Bussel J, Orazi A. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. Br J Haematol. 2019;185:136–42.
doi: 10.1111/bjh.15386
pubmed: 29767848
Kucine N. Myeloproliferative neoplasms in children, adolescents and young adults. Curr Hematol Malig. 2020;15:141–6.
doi: 10.1007/s11899-020-00571-8
Kröger N, Chalandon Y Myeloproliferative Neoplasms. In: Varreras E, Dufour C, Mohty M, Kröger N (Eds.). EBMT Handbook – Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer Open, 2019, pp. 569-78.
Domm J, Calder C, Manes B, Crossno C, Correa H, Frangoul H. Unrelated stem cell transplant for infantile idiopathic myelofibrosis. Pediatr Blood Cancer. 2009;52:893–5.
doi: 10.1002/pbc.21910
pubmed: 19241452
Shaikh F, Naithani R, Kirby-Allen M, Doyle L. Allogeneic cord hematopoietic stem cell transplantation in an infant with primary myelofibrosis. J Pediatr Hematol Oncol. 2012;34:199–201.
doi: 10.1097/MPH.0b013e3182346cc5
Hussein AA, Domm HT, Al-Zaben A, Frangoul H. Allogeneic hematopoietic stem cell transplantation for infants with idiopathic myelofibrosis. Pediatr Transplantation. 2013;17:815–9.
doi: 10.1111/petr.12148
Mitton B, de Oliveira S, Pullarkat ST, Moore TB. Stem cell transplantation in primary myelofibrosis of childhood. J Pediatr Hematol Oncol. 2013;35:e120–e122.
doi: 10.1097/MPH.0b013e31828800cc
pubmed: 23511496
Valcárcel D, Sureda A Graft failure. In: Carreas E, Dufour C, Mohty M, Kröger N (eds). The EBMT Handbook. Springer International Publishing, 2019. Pp 307-13. http://link.springer.com/10.1007/978-3-030-02278-5_41 .
McLornan DP, Boluda JCH, Czerw T, Cross N, Deeg HJ, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35:2445–59.
doi: 10.1038/s41375-021-01294-2
pubmed: 34040148
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
pubmed: 16338616
Rosbach HC. Familial infantile myelofibrosis as an autosomal recesseive disorder: preponderance among children from Saudi Arabia. Pediatr Hematol Oncol. 2006;23:453–4.
doi: 10.1080/08880010600623240
McLornan D, Eikema DJ, Czerw T, Kröger N, Koster R, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transplant. 2021;56:2160–72.
doi: 10.1038/s41409-021-01305-x
pubmed: 33911203
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310–8.
doi: 10.1200/JCO.2017.76.4886
pubmed: 29226763
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29:2126–33.
doi: 10.1038/leu.2015.233
pubmed: 26293647
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726–31.
doi: 10.1038/leu.2017.169
pubmed: 28561069
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassimat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–342.
doi: 10.1182/blood-2018-12-890889
pubmed: 30760453
DeLario MR, Sheehan AM, Ataya R, Bertuch AA, Vega CII, Webb CR, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis – an entity different from adults. Am J Hematol. 2012;87:461–5.
doi: 10.1002/ajh.23140
pubmed: 22389089
Wachowiak J, Sykora K-W, Cornish J, Chybicka A, Kowalczyk JR, Gorczyńska E, et al. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT Pediatric Diseases Working Party. Bone Marrow Transplant. 2011;4:1510–8.
doi: 10.1038/bmt.2010.343
Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023;108:1900–8.
doi: 10.3324/haematol.2022.281958
pubmed: 36779595
pmcid: 10316233
Perram J, Ross DM, McLornan D, Gowin K, Kröger N, Gupta V, et al. Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. Am J Hematol. 2022;97:1464–77.
doi: 10.1002/ajh.26654
pubmed: 35802782
pmcid: 9796730
Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226–33.
doi: 10.1182/blood.V95.7.2226
pubmed: 10733489
Malato A, Rossi E, Tiribelli M, Mendicino F, Pugliese N. Splenectomy in myelofibrosis: indications, efficacy, and complications. Clin Lymphoma Myeloma Leuk. 2020;20:588–95.
doi: 10.1016/j.clml.2020.04.015
pubmed: 32482540
Gagelmann N, Kröger N. Improving allogeneic stem cell transplantation in myelofibrosis. Int J Hematol. 2022;115:619–25.
doi: 10.1007/s12185-022-03340-w
pubmed: 35419771